{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T10:43:48Z","timestamp":1788173028826,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T00:00:00Z","timestamp":1655683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejpn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ejpn.2022.06.007","type":"journal-article","created":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T11:34:16Z","timestamp":1654947256000},"page":"74-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Drug-induced hyperthermia with rhabdomyolysis in CLN3 disease"],"prefix":"10.1016","volume":"39","author":[{"given":"A.","family":"Savvidou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Jennions","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wikstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Olsson-Engman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Sofou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Darin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpn.2022.06.007_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1684\/epd.2016.0844","article-title":"Neuronal ceroid lipofuscinoses","volume":"18","author":"Nita","year":"2016","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.ejpn.2022.06.007_bib2","first-page":"73","article-title":"Juvenile neuronal ceroid lipofuscinosis (Batten disease): current insights","volume":"6","author":"Ostergaard","year":"2016","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"10.1016\/j.ejpn.2022.06.007_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.autneu.2018.07.003","article-title":"Paroxysmal sympathetic hyperactivity in Juvenile neuronal ceroid lipofuscinosis (Batten disease)","volume":"214","author":"Ostergaard","year":"2018","journal-title":"Auton. Neurosci."},{"key":"10.1016\/j.ejpn.2022.06.007_bib4","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1177\/0883073813494813","article-title":"Neurobehavioral features and natural history of juvenile neuronal ceroid lipofuscinosis (Batten disease)","volume":"28","author":"Adams","year":"2013","journal-title":"J.\u00a0Child Neurol."},{"key":"10.1016\/j.ejpn.2022.06.007_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2788.2005.00659.x","article-title":"Psychiatric symptoms of children and adolescents with juvenile neuronal ceroid lipofuscinosis","volume":"49","author":"Backman","year":"2005","journal-title":"J.\u00a0Intellect. Disabil. Res."},{"issue":"Suppl A","key":"10.1016\/j.ejpn.2022.06.007_bib6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1053\/ejpn.2000.0455","article-title":"New antidepressive and antipsychotic drugs in juvenile neuronal ceroid lipofuscinoses--a pilot study","volume":"5","author":"Backman","year":"2001","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.ejpn.2022.06.007_bib7","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/qjmed\/hcg109","article-title":"The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity","volume":"96","author":"Dunkley","year":"2003","journal-title":"QJM"},{"key":"10.1016\/j.ejpn.2022.06.007_bib8","series-title":"Neuroleptic Malignant Syndrome StatPearls","author":"Simon","year":"2021"},{"key":"10.1016\/j.ejpn.2022.06.007_bib9","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1176\/ajp.148.6.705","article-title":"The serotonin syndrome","volume":"148","author":"Sternbach","year":"1991","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.ejpn.2022.06.007_bib10","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/B978-0-444-64074-1.00039-2","article-title":"Neuroleptic malignant syndrome and serotonin syndrome","volume":"157","author":"Tormoehlen","year":"2018","journal-title":"Handb. Clin. Neurol."},{"key":"10.1016\/j.ejpn.2022.06.007_bib11","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2147\/NDT.S118438","article-title":"Neuroleptic malignant syndrome: an easily overlooked neurologic emergency","volume":"13","author":"Oruch","year":"2017","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.ejpn.2022.06.007_bib12","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMra041867","article-title":"The serotonin syndrome","volume":"352","author":"Boyer","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejpn.2022.06.007_bib13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11940-016-0423-4","article-title":"Management of serotonin syndrome and neuroleptic malignant syndrome","volume":"18","author":"Katus","year":"2016","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.ejpn.2022.06.007_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/104012371202400208","article-title":"Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management","volume":"24","author":"Perry","year":"2012","journal-title":"Ann. Clin. Psychiatr."},{"key":"10.1016\/j.ejpn.2022.06.007_bib15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/jnnp.74.3.385","article-title":"Neuroleptic malignant syndrome in Kufs' disease","volume":"74","author":"Reif","year":"2003","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejpn.2022.06.007_bib16","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1023\/A:1025916518457","article-title":"Neuroleptic malignant syndrome in juvenile neuronal ceroid lipofuscinosis associated with low-dose risperidone therapy","volume":"26","author":"Vercammen","year":"2003","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.ejpn.2022.06.007_bib17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1176\/ajp.156.2.169","article-title":"Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome","volume":"156","author":"Gurrera","year":"1999","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.ejpn.2022.06.007_bib18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0079-6123(06)62006-2","article-title":"Neuroleptic malignant syndrome and serotonin syndrome","volume":"162","author":"Nisijima","year":"2007","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.ejpn.2022.06.007_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.0924-2708.2004.00085.x","article-title":"Neuroleptic malignant syndrome: risk factors, pathophysiology, and treatment","volume":"16","author":"Ananth","year":"2004","journal-title":"Acta Neuropsychiatr."},{"key":"10.1016\/j.ejpn.2022.06.007_bib20","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1212\/WNL.54.5.1069","article-title":"Decreased striatal dopamine transporter density in JNCL patients with parkinsonian symptoms","volume":"54","author":"Aberg","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2022.06.007_bib21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00002826-200207000-00001","article-title":"Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia?","volume":"25","author":"Gurrera","year":"2002","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.ejpn.2022.06.007_bib22","first-page":"58","article-title":"Are neuroleptic malignant syndrome and serotonin syndrome the same syndrome?","volume":"47","author":"Steele","year":"2011","journal-title":"Psychiatr. Care"},{"key":"10.1016\/j.ejpn.2022.06.007_bib23","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ajem.2020.06.046","article-title":"A\u00a0diagnostic confusion between Serotonin syndrome and Neuroleptic malignant syndrome","volume":"43","author":"Prakash","year":"2021","journal-title":"Am. J. Emerg. Med."},{"key":"10.1016\/j.ejpn.2022.06.007_bib24","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/acps.12694","article-title":"A\u00a0systematic review of sex and age factors in neuroleptic malignant syndrome diagnosis frequency","volume":"135","author":"Gurrera","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.ejpn.2022.06.007_bib25","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/acn3.662","article-title":"Autophagic vacuolar myopathy is a common feature of CLN3 disease","volume":"5","author":"Radke","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.ejpn.2022.06.007_bib26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.yebeh.2019.02.020","article-title":"Epileptological aspects of juvenile neuronal ceroid lipofuscinosis (CLN3 disease) through the lifespan","volume":"94","author":"Arntsen","year":"2019","journal-title":"Epilepsy Behav."}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379822000940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379822000940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:39:28Z","timestamp":1761071968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379822000940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":26,"alternative-id":["S1090379822000940"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2022.06.007","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced hyperthermia with rhabdomyolysis in CLN3 disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2022.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.","name":"copyright","label":"Copyright"}]}}